Gastrointestinal stromal tumors can respond to imatinib mesylate therapy owing to its inhibitory action on tumor cells as well as off-target effects on NK cells. This report shows that a different frequency of genetically determined expression profiles of isoforms of the NK cell receptor NKp30, which show various functional properties, is associated with GIST and influences survival after imatinib treatment.
- Nicolas F Delahaye
- Sylvie Rusakiewicz
- Laurence Zitvogel
